Doxorubicin-eluting beads - BTG

Drug Profile

Doxorubicin-eluting beads - BTG

Alternative Names: DC Bead; DEBDOX; Doxorubicin-loaded DC Bead LUMI™; E7040; Embolic bead; LifePearl; PRECISION Bead

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocompatibles International; Eisai Co Ltd
  • Developer Biocompatibles International; BTG; Eisai Co Ltd; SciClone Pharmaceuticals; Terumo
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatocellular carcinoma; Vascular disorders
  • No development reported Lung cancer

Most Recent Events

  • 01 Mar 2017 No development reported - Phase-II for Hepatocellular carcinoma in USA (Intra-arterial)
  • 29 Sep 2015 Doxorubicin eluting beads receives approval for Hypervascular tumours in Japan
  • 29 Sep 2015 Launched for Vascular disorders in Japan (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top